Pleurectomy/decortication can be completed safely in select patients with pleural mesothelioma with low postoperative mortality, according to findings from a study published in The Annals of Thoracic Surgery. “Our findings show that pleurectomy/decortication can be done safely when patients are … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Cancer and Disease Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Lawsuits
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Our "Recent Articles" Archives
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent Articles
Ozempic Eye Stroke Side Effect Rates Study 2026
Non-arteritic anterior ischemic optic neuropathy (NAION) is a vision-related drug side effect commonly referred to as an "eye stroke". In this post, we focus on a new Ozempic eye stroke side effect rates study published in the March 2026 British Journal of Ophthalmology article, "Ischemic optic … More
NAION Ozempic Side-Effect Warning: Novo Nordisk Failure
We have written about the NAION Ozempic side-effect warning issue several times over the past year-and-a-half, and have repeatedly pointed out that non-arteritic anterior ischemic optic neuropathy, or NAION, is linked to semaglutide. Moreover, we noted that semaglutide is the active ingredient in … More
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Treatments: CheckMate 743 Study [Opdivo plus Yervoy treatments have] demonstrated long-term, durable survival benefit as first-line treatment in patients with various solid tumor types. The randomized phase III CheckMate 743 study demonstrated significant … More
NAION Vision Loss With Ozempic, Wegovy, and Rybelsus: New Medical Evidence in 2026
Ozempic, Wegovy, and Rybelsus are semaglutide-containing drugs from Novo Nordisk. Starting in 2024, there have been reports of non-arteritic anterior ischemic optic neuropathy, or NAION, associated with these semaglutide-containing drugs. And there is new medical evidence in 2026 regarding NAION … More
Rybelsus Lawsuits for Pancreatitis Death Cases
We are investigating Rybelsus lawsuits, with a focus on cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death. Those Rybeslus pancreatitis death cases would be filed against the responsible pharmaceutical company, Novo Nordisk. The best Rybelsus lawsuits would be for … More